Buy Stocks Easy | About Us
June 29, 2022
Buy Stocks Easy | Online Stocks

AZRX


Buy AzurRx BioPharma, Inc. Stock (symbol: AZRX) Easy Online

Company Name: AzurRx BioPharma, Inc.

Symbol: AZRX

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2016

AZRX Current Share Price

Today's AZRX ( AzurRx BioPharma, Inc. ) opening price: $1.0000

Yesterday's AZRX ( AzurRx BioPharma, Inc. ) closing price: $0.9950

AzurRx BioPharma, Inc. Stock ( symbol: AZRX ) Price Chart since IPO (2016):

12 Months AzurRx BioPharma, Inc. Stock ( symbol: AZRX ) Price Chart

Popular Questions about AzurRx BioPharma, Inc. Public Stock ( AZRX )

A: AzurRx BioPharma, Inc. stock symbol (also called stock or share ticker) is AZRX

A: AzurRx BioPharma, Inc. IPO (Initial Public Offering) took place on 2016

A: AzurRx BioPharma, Inc.'s stock (AZRX symbol) price at ther IPO (initial Public Offering) was $1.0000

Q: Is AZRX stock worth buying at the moment?

A: The AZRX stock performance since 2019 are rather disappointing. If you had bought 1 share of AzurRx BioPharma, Inc. stock (symbol: AZRX) at the beginning of 2019, at the opening share price of $2.1127, you would be left with exactly $1.0000 - which means a waste of your money and time. - SHOW ONLY IF equal or loose.

Buy AzurRx BioPharma, Inc. Stock Easy Online

AzurRx BioPharma, Inc. Stock Ticker Price Chart since IPO:





AzurRx BioPharma, Inc. Stock Price Yesterday



 


AzurRx BioPharma, Inc. Stock Price – Last Week




 


AzurRx BioPharma, Inc. Stock Price – Last Month




 


AzurRx BioPharma, Inc. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/14/1947191/0/en/AzurRx-BioPharma-Inc-Announces-Equity-Purchase-Agreement-for-up-to-15-Million-with-Lincoln-Park-Capital-Fund-LLC.html
                            

                                
AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

                                
                                
NEW YORK, Nov.  14, 2019  (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/22/1933147/0/en/AzurRx-BioPharma-CEO-Issues-Letter-to-Shareholders.html
                            

                                
AzurRx BioPharma CEO Issues Letter to Shareholders

                                
                                
NEW YORK, Oct.  22, 2019  (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/17/1931500/0/en/AzurRx-BioPharma-Announces-Positive-CFF-DSMB-Review-of-Final-Phase-2-OPTION-Trial-Data.html
                            

                                
AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data

                                
                                
NEW YORK, Oct.  17, 2019  (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/15/1929591/0/en/AzurRx-BioPharma-Announces-First-Patients-Dosed-in-Clinical-Study-for-MS1819-SD-in-combination-with-PERT-for-Cystic-Fibrosis-Patients-with-Severe-Exocrine-Pancreatic-Insufficiency.html
                            

                                
AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

                                
                                
NEW YORK, Oct.  15, 2019  (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/10/1927932/0/en/AzurRx-BioPharma-Announces-Appointment-of-James-Sapirstein-as-Chief-Executive-Officer.html
                            

                                
AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer

                                
                                
Founder and Former CEO Thijs Spoor to Remain on Board of Directors ...


                            

                        
                    

                


                            

                    


                        
                            https://www.benzinga.com/general/biotech/19/09/14487759/azurrx-shares-tank-on-unimpressive-efficacy-data-for-biologic-drug-to-treat-pancreatic-insufficie
                            

                                
AzurRx Shares Tank On Unimpressive Efficacy Data For Biologic Drug To Treat Pancreatic Insufficiency

                                
                                
Shares of thinly-traded nano-cap biotech AzurRx BioPharma Inc (NASD...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/25/1920526/0/en/AzurRx-BioPharma-Announces-Positive-Results-from-Phase-2-Trial-with-MS1819-in-Cystic-Fibrosis-Patients.html
                            

                                
AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients

                                
                                
Excellent safety results seen in CF patients, with CFA in line with...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/14/1947191/0/en/AzurRx-BioPharma-Inc-Announces-Equity-Purchase-Agreement-for-up-to-15-Million-with-Lincoln-Park-Capital-Fund-LLC.html
                            

                                
AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

                                
                                
NEW YORK, Nov.  14, 2019  (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/22/1933147/0/en/AzurRx-BioPharma-CEO-Issues-Letter-to-Shareholders.html
                            

                                
AzurRx BioPharma CEO Issues Letter to Shareholders

                                
                                
NEW YORK, Oct.  22, 2019  (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/17/1931500/0/en/AzurRx-BioPharma-Announces-Positive-CFF-DSMB-Review-of-Final-Phase-2-OPTION-Trial-Data.html
                            

                                
AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data

                                
                                
NEW YORK, Oct.  17, 2019  (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/15/1929591/0/en/AzurRx-BioPharma-Announces-First-Patients-Dosed-in-Clinical-Study-for-MS1819-SD-in-combination-with-PERT-for-Cystic-Fibrosis-Patients-with-Severe-Exocrine-Pancreatic-Insufficiency.html
                            

                                
AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

                                
                                
NEW YORK, Oct.  15, 2019  (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/10/1927932/0/en/AzurRx-BioPharma-Announces-Appointment-of-James-Sapirstein-as-Chief-Executive-Officer.html
                            

                                
AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer

                                
                                
Founder and Former CEO Thijs Spoor to Remain on Board of Directors ...


                            

                        
                    

                


                            

                    


                        
                            https://www.benzinga.com/general/biotech/19/09/14487759/azurrx-shares-tank-on-unimpressive-efficacy-data-for-biologic-drug-to-treat-pancreatic-insufficie
                            

                                
AzurRx Shares Tank On Unimpressive Efficacy Data For Biologic Drug To Treat Pancreatic Insufficiency

                                
                                
Shares of thinly-traded nano-cap biotech AzurRx BioPharma Inc (NASD...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/25/1920526/0/en/AzurRx-BioPharma-Announces-Positive-Results-from-Phase-2-Trial-with-MS1819-in-Cystic-Fibrosis-Patients.html
                            

                                
AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients

                                
                                
Excellent safety results seen in CF patients, with CFA in line with...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.